Incyte
INCY----
Q3 FY2026 EarningsQ3 FY26 results beat consensus on both top and bottom lines, with total revenue of $1.56B exceeding the $1.46B expected (+6.5% variance). Non-GAAP diluted EPS of -$3.60 beat the expected -$3.87, despite a significant -$1.23B IPR&D charge from the Vega acquisition. Management raised FY26 total net sales guidance to $5.21B - $5.30B, reflecting strong 36% YoY growth in Opzelura and 38% in Hematology/Oncology portfolios.
Financial report interval: 2026.06.30 - 2026.09.30
Overview: Incyte(INCY) the Revenue is 1.557 B (+14%), Beat estimate;the EBIT is -629.72 M (-226.4%), Beat estimate;the EPS is -3.86 (-282.9%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
1.56B14.00%
1.46B7.06%
+0.09B6.94%
EBITExceed expectations
-0.63B226.37%
-0.78B255.57%
+0.15B29.20%
EPSExceed expectations
-3.86282.94%
-4.2538301.60%
+0.393818.66%
Upcoming earnings report - Annual FY2026
Available dateFeb 9, 2027
Estimate Revenue$6.062 B
Estimate EBIT$992.49 M
Estimate EPS$2.1668
Revenue
ActualEstimateUnit: USD
Quarterly
EBIT
ActualEstimateUnit: USD
Quarterly
Net income
ActualEstimateUnit: USD
Quarterly
EPS
ActualEstimateUnit: USD
Quarterly